From cancer metabolism to new biomarkers and drug targets

Biotechnology Advances

Volumn 30, Issue 1, 2012, Pages 30-51

  Chiaradonna, F ^a   Moresco, R M ^a,b,c   Airoldi, C ^a   Gaglio, D ^a   Palorini, R ^a   Nicotra, F ^a   Messa, C ^a,b,c   Alberghina, L ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c INSTITUTE OF MOLECULAR BIOIMAGING AND PHYSIOLOGY   (Italy)

Author keywords

Cancer; Drug discovery; Mass spectrometry; Metabolism; NMR; PET; Systems biology

Indexed keywords

CANCER; CANCER CELLS; CLINICAL APPLICATION; DRUG DISCOVERY; DRUG TARGETS; FATTY ACID SYNTHESIS; HUMAN TUMORS; INDUSTRIAL ACTIVITIES; METABOLIC CHANGES; METABOLIC FLUX ANALYSIS; METABOLOMES; MITOCHONDRIAL FUNCTION; MOLECULAR BASIS; SYSTEM LEVELS; SYSTEMS BIOLOGY;

AMINO ACIDS; CELL DEATH; CELL PROLIFERATION; FATTY ACIDS; MASS SPECTROMETRY; METABOLISM; NUCLEAR MAGNETIC RESONANCE; PHYSIOLOGY; POLYETHYLENE TEREPHTHALATES; POSITRON EMISSION TOMOGRAPHY;

DISEASES;

ANTINEOPLASTIC AGENT; TUMOR MARKER;

APOPTOSIS; CANCER; DRUG; FATTY ACID; MASS SPECTROMETRY; METABOLISM; NUCLEAR MAGNETIC RESONANCE; TUMOR;

ANIMAL; HUMAN; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASM; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; METABOLIC NETWORKS AND PATHWAYS; MOLECULAR TARGETED THERAPY; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84855719307     PISSN: 07349750     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biotechadv.2011.07.006     Document Type: Review

References (306)

1. Abercrombie M. Contact inhibition and malignancy. Nature 1979, 281:259-262.
2. Abraham R.T., Gibbons J.J. The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. Clin Cancer Res 2007, 13:3109-3114.
3. Acin-Perez R., Salazar E., Kamenetsky M., Buck J., Levin L.R., Manfredi G. Cyclic AMP produced inside mitochondria regulates oxidative phosphorylation. Cell Metab 2009, 9:265-276.
4. Alberghina L., Chiaradonna F., Vanoni M. Systems biology and the molecular circuits of cancer. Chembiochem 2004, 5:1322-1333.
5. Alberghina L., Hofer T., Vanoni M. Molecular networks and system-level properties. J Biotechnol 2009, 144:224-233.
6. Alchanati I., Nallar S.C., Sun P., Gao L., Hu J., Stein A., Yakirevich E., Konforty D., Alroy I., Zhao X., et al. A proteomic analysis reveals the loss of expression of the cell death regulatory gene GRIM-19 in human renal cell carcinomas. Oncogene 2006, 25:7138-7147.
7. Alimova I.N., Liu B., Fan Z., Edgerton S.M., Dillon T., Lind S.E., Thor A.D. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 2009, 8:909-915.
8. Alirol E., Martinou J.C. Mitochondria and cancer: is there a morphological connection?. Oncogene 2006, 25:4706-4716.
9. Amendola D., De Salvo M., Marchese R., Verga Falzacappa C., Stigliano A., Carico E., Brunetti E., Moscarini M., Bucci B. Myc down-regulation affects cyclin D1/cdk4 activity and induces apoptosis via Smac/Diablo pathway in an astrocytoma cell line. Cell Prolif 2009, 42:94-109.
10. An Z., Chen Y., Zhang R., Song Y., Sun J., He J., Bai J., Dong L., Zhan Q., Abliz Z. Integrated ionization approach for RRLC-MS/MS-based metabonomics: finding potential biomarkers for lung cancer. J Proteome Res 2010, 9:4071-4081.
11. Ardawi M.S., Majzoub M.F., Masoud I.M., Newsholme E.A. Enzymic and metabolic adaptations in the gastrocnemius, plantaris and soleus muscles of hypocaloric rats. Biochem J 1989, 261:219-225.
12. Aukema T.S., Kappers I., Olmos R.A., Codrington H.E., van Tinteren H., van Pel R., Klomp H.M. Is 18F-FDG PET/CT useful for the early prediction of histopathologic response to neoadjuvant erlotinib in patients with non-small cell lung cancer?. J Nucl Med 2010, 51:1344-1348.
13. Baracca A., Chiaradonna F., Sgarbi G., Solaini G., Alberghina L., Lenaz G. Mitochondrial Complex I decrease is responsible for bioenergetic dysfunction in K-ras transformed cells. Biochim Biophys Acta 2010, 1797:314-323.
14. Baron A., Migita T., Tang D., Loda M. Fatty acid synthase: a metabolic oncogene in prostate cancer?. J Cell Biochem 2004, 91:47-53.
15. Bartrons R., Caro J. Hypoxia, glucose metabolism and the Warburg's effect. J Bioenerg Biomembr 2007, 39:223-229.
16. Basu S., Zhuang H., Torigian D.A., Rosenbaum J., Chen W., Alavi A. Functional imaging of inflammatory diseases using nuclear medicine techniques. Semin Nucl Med 2009, 39:124-145.
17. Beckonert O., Coen M., Keun H.C., Wang Y., Ebbels T.M., Holmes E., Lindon J.C., Nicholson J.K. High-resolution magic-angle-spinning NMR spectroscopy for metabolic profiling of intact tissues. Nat Protoc 2010, 5:1019-1032.
18. Ben Sahra I., Laurent K., Giuliano S., Larbret F., Ponzio G., Gounon P., Le Marchand-Brustel Y., Giorgetti-Peraldi S., Cormont M., Bertolotto C., et al. Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res 2010, 70:2465-2475.
19. Benard G., Bellance N., James D., Parrone P., Fernandez H., Letellier T., Rossignol R. Mitochondrial bioenergetics and structural network organization. J Cell Sci 2007, 120:838-848.
20. Bensaad K., Tsuruta A., Selak M.A., Vidal M.N., Nakano K., Bartrons R., Gottlieb E., Vousden K.H. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 2006, 126:107-120.
21. Bergstrom J., Furst P., Noree L.O., Vinnars E. Intracellular free amino acid concentration in human muscle tissue. J Appl Physiol 1974, 36:693-697.
22. Biaglow J.E., Cerniglia G., Tuttle S., Bakanauskas V., Stevens C., McKenna G. Effect of oncogene transformation of rat embryo cells on cellular oxygen consumption and glycolysis. Biochem Biophys Res Commun 1997, 235:739-742.
23. Bissler J.J., McCormack F.X., Young L.R., Elwing J.M., Chuck G., Leonard J.M., Schmithorst V.J., Laor T., Brody A.S., Bean J., et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008, 358:140-151.
24. Blaise B.J., Giacomotto J., Elena B., Dumas M.E., Toulhoat P., Segalat L., Emsley L. Metabotyping of Caenorhabditis elegans reveals latent phenotypes. Proc Natl Acad Sci USA 2007, 104:19808-19812.
25. Blaise B.J., Giacomotto J., Triba M.N., Toulhoat P., Piotto M., Emsley L., Segalat L., Dumas M.E., Elena B. Metabolic profiling strategy of Caenorhabditis elegans by whole-organism nuclear magnetic resonance. J Proteome Res 2009, 8:2542-2550.
26. Boeck S., Heinemann V. Anti-epidermal growth factor receptor treatment strategies in advanced pancreatic cancer: success or failure?. J Clin Oncol 2010, 29:e70-71. author reply e72-73.
27. Bonnet S., Archer S.L., Allalunis-Turner J., Haromy A., Beaulieu C., Thompson R., Lee C.T., Lopaschuk G.D., Puttagunta L., Harry G., et al. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 2007, 11:37-51.
28. Bonora E., Porcelli A.M., Gasparre G., Biondi A., Ghelli A., Carelli V., Baracca A., Tallini G., Martinuzzi A., Lenaz G., et al. Defective oxidative phosphorylation in thyroid oncocytic carcinoma is associated with pathogenic mitochondrial DNA mutations affecting complexes I and III. Cancer Res 2006, 66:6087-6096.
29. Bouchelouche K., Oehr P. Recent developments in urologic oncology: positron emission tomography molecular imaging. Curr Opin Oncol 2008, 20:321-326.
30. Boultwood J., Fidler C., Mills K.I., Frodsham P.M., Kusec R., Gaiger A., Gale R.E., Linch D.C., Littlewood T.J., Moss P.A., et al. Amplification of mitochondrial DNA in acute myeloid leukaemia. Br J Haematol 1996, 95:426-431.
31. Brachmann S., Fritsch C., Maira S.M., Garcia-Echeverria C. PI3K and mTOR inhibitors: a new generation of targeted anticancer agents. Curr Opin Cell Biol 2009, 21:194-198.
32. Brachmann S.M., Hofmann I., Schnell C., Fritsch C., Wee S., Lane H., Wang S., Garcia-Echeverria C., Maira S.M. Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proc Natl Acad Sci USA 2009, 106:22299-22304.
33. Brahimi-Horn M.C., Chiche J., Pouyssegur J. Hypoxia and cancer. J Mol Med 2007, 85:1301-1307.
34. Brown R.S., Wahl R.L. Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study. Cancer 1993, 72:2979-2985.
35. Buzzai M., Bauer D.E., Jones R.G., Deberardinis R.J., Hatzivassiliou G., Elstrom R.L., Thompson C.B. The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid beta-oxidation. Oncogene 2005, 24:4165-4173.
36. Buzzai M., Jones R.G., Amaravadi R.K., Lum J.J., DeBerardinis R.J., Zhao F., Viollet B., Thompson C.B. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 2007, 67:6745-6752.
37. Cai Y., Martens G.A., Hinke S.A., Heimberg H., Pipeleers D., Van de Casteele M. Increased oxygen radical formation and mitochondrial dysfunction mediate beta cell apoptosis under conditions of AMP-activated protein kinase stimulation. Free Radic Biol Med 2007, 42:64-78.
38. Carlucci A., Lignitto L., Feliciello A. Control of mitochondria dynamics and oxidative metabolism by cAMP, AKAPs and the proteasome. Trends Cell Biol 2008, 18:604-613.
39. Chandra D., Singh K.K. Genetic insights into OXPHOS defect and its role in cancer. Biochim Biophys Acta 2010, 1807:620-625.
40. Chang C.R., Blackstone C. Cyclic AMP-dependent protein kinase phosphorylation of Drp1 regulates its GTPase activity and mitochondrial morphology. J Biol Chem 2007, 282:21583-21587.
41. Chen H., Chomyn A., Chan D.C. Disruption of fusion results in mitochondrial heterogeneity and dysfunction. J Biol Chem 2005, 280:26185-26192.
42. Chen H., Vermulst M., Wang Y.E., Chomyn A., Prolla T.A., McCaffery J.M., Chan D.C. Mitochondrial fusion is required for mtDNA stability in skeletal muscle and tolerance of mtDNA mutations. Cell 2010, 141:280-289.
43. Cheng L.L., Lean C.L., Bogdanova A., Wright S.C., Ackerman J.L., Brady T.J., Garrido L. Enhanced resolution of proton NMR spectra of malignant lymph nodes using magic-angle spinning. Magn Reson Med 1996, 36:653-658.
44. Chiaradonna F., Gaglio D., Vanoni M., Alberghina L. Expression of transforming K-Ras oncogene affects mitochondrial function and morphology in mouse fibroblasts. Biochim Biophys Acta 2006, 1757:1338-1356.
45. Chiaradonna F., Sacco E., Manzoni R., Giorgio M., Vanoni M., Alberghina L. Ras-dependent carbon metabolism and transformation in mouse fibroblasts. Oncogene 2006, 25:5391-5404.
46. Chiorean E.G., Dragovich T., Hamm J., Barrios C.H., Gorini C.F., Langmuir V.K., Kroll S., Jung D.T., Tidmarsh G.T., Loehrer P.J. A phase 2 trial of glufosfamide in combination with gemcitabine in chemotherapy-naive pancreatic adenocarcinoma. Am J Clin Oncol 2010, 33:111-116.
47. Chomyn A., Attardi G. MtDNA mutations in aging and apoptosis. Biochem Biophys Res Commun 2003, 304:519-529.
48. Christofk H.R., Vander Heiden M.G., Harris M.H., Ramanathan A., Gerszten R.E., Wei R., Fleming M.D., Schreiber S.L., Cantley L.C. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008, 452:230-233.
49. Chun S.Y., Johnson C., Washburn J.G., Cruz-Correa M.R., Dang D.T., Dang L.H. Oncogenic KRAS modulates mitochondrial metabolism in human colon cancer cells by inducing HIF-1alpha and HIF-2alpha target genes. Mol Cancer 2010, 9:293.
50. Corradetti M.N., Inoki K., Bardeesy N., DePinho R.A., Guan K.L. Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. Genes Dev 2004, 18:1533-1538.
51. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420:860-867.
52. Cribbs J.T., Strack S. Reversible phosphorylation of Drp1 by cyclic AMP-dependent protein kinase and calcineurin regulates mitochondrial fission and cell death. EMBO Rep 2007, 8:939-944.
53. Croteau D.L., Bohr V.A. Repair of oxidative damage to nuclear and mitochondrial DNA in mammalian cells. J Biol Chem 1997, 272:25409-25412.
54. Cuezva J.M., Krajewska M., de Heredia M.L., Krajewski S., Santamaria G., Kim H., Zapata J.M., Marusawa H., Chamorro M., Reed J.C. The bioenergetic signature of cancer: a marker of tumor progression. Cancer Res 2002, 62:6674-6681.
55. Cullinane C., Dorow D.S., Kansara M., Conus N., Binns D., Hicks R.J., Ashman L.K., McArthur G.A., Thomas D.M. An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug development. Cancer Res 2005, 65:9633-9636.
56. Czernin J., Allen-Auerbach M., Schelbert H.R. Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006. J Nucl Med 2007, 48(Suppl 1):78S-88S.
57. da Silva Morais A., Saliez A., Leclercq I., Horsmans Y., Starkel P. Inhibition of the Ras oncoprotein reduces proliferation of hepatocytes in vitro and in vivo in rats. Clin Sci (Lond) 2008, 114:73-83.
58. Dang C.V., Kim J.W., Gao P., Yustein J. The interplay between MYC and HIF in cancer. Nat Rev Cancer 2008, 8:51-56.
59. Dang C.V., Semenza G.L. Oncogenic alterations of metabolism. Trends Biochem Sci 1999, 24:68-72.
60. Dang L., White D.W., Gross S., Bennett B.D., Bittinger M.A., Driggers E.M., Fantin V.R., Jang H.G., Jin S., Keenan M.C., et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009, 462:739-744.
61. De Rasmo D., Panelli D., Sardanelli A.M., Papa S. cAMP-dependent protein kinase regulates the mitochondrial import of the nuclear encoded NDUFS4 subunit of complex I. Cell Signal 2008, 20:989-997.
62. De Rasmo D., Signorile A., Papa F., Roca E., Papa S. cAMP/Ca2+ response element-binding protein plays a central role in the biogenesis of respiratory chain proteins in mammalian cells. IUBMB Life 2010, 62:447-452.
63. De Rasmo D., Signorile A., Roca E., Papa S. cAMP response element-binding protein (CREB) is imported into mitochondria and promotes protein synthesis. FEBS J 2009, 276:4325-4333.
64. DeBerardinis R.J., Cheng T. Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene 2009, 29:313-324.
65. DeBerardinis R.J., Lum J.J., Hatzivassiliou G., Thompson C.B. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008, 7:11-20.
66. DeBerardinis R.J., Mancuso A., Daikhin E., Nissim I., Yudkoff M., Wehrli S., Thompson C.B. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci USA 2007, 104:19345-19350.
67. Deberardinis R.J., Sayed N., Ditsworth D., Thompson C.B. Brick by brick: metabolism and tumor cell growth. Curr Opin Genet Dev 2008, 18:54-61.
68. Decensi A., Puntoni M., Goodwin P., Cazzaniga M., Gennari A., Bonanni B., Gandini S. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila) 2010, 3:1451-1461.
69. Degenhardt K., Mathew R., Beaudoin B., Bray K., Anderson D., Chen G., Mukherjee C., Shi Y., Gelinas C., Fan Y., et al. Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell 2006, 10:51-64.
70. Dempke W.C., Heinemann V. Resistance to EGF-R (erbB-1) and VEGF-R modulating agents. Eur J Cancer 2009, 45:1117-1128.
71. Dowling R.J., Zakikhani M., Fantus I.G., Pollak M., Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 2007, 67:10804-10812.
72. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003, 3:11-22.
73. Drogat B., Bouchecareilh M., North S., Petibois C., Deleris G., Chevet E., Bikfalvi A., Moenner M. Acute l-glutamine deprivation compromises VEGF-a upregulation in A549/8 human carcinoma cells. J Cell Physiol 2007, 212:463-472.
74. Dumaz N., Marais R. Integrating signals between cAMP and the RAS/RAF/MEK/ERK signalling pathways. Based on the anniversary prize of the Gesellschaft fur Biochemie und Molekularbiologie Lecture delivered on 5 July 2003 at the Special FEBS Meeting in Brussels. FEBS J 2005, 272:3491-3504.
75. Dunn W.B., Ellis D.I. Metabolomics: current analytical platforms and methodologies. Trends Anal Chem 2005, 24:285-294.
76. Dwarakanath B.S., Khaitan D., Ravindranath T. 2-deoxy-d-glucose enhances the cytotoxicity of topoisomerase inhibitors in human tumor cell lines. Cancer Biol Ther 2004, 3:864-870.
77. Eagle H., Levine E.M. Growth regulatory effects of cellular interaction. Nature 1967, 213:1102-1106.
78. Egler V., Korur S., Failly M., Boulay J.L., Imber R., Lino M.M., Merlo A. Histone deacetylase inhibition and blockade of the glycolytic pathway synergistically induce glioblastoma cell death. Clin Cancer Res 2008, 14:3132-3140.
79. Elstrom R.L., Bauer D.E., Buzzai M., Karnauskas R., Harris M.H., Plas D.R., Zhuang H., Cinalli R.M., Alavi A., Rudin C.M., et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 2004, 64:3892-3899.
80. Engelman J.A., Chen L., Tan X., Crosby K., Guimaraes A.R., Upadhyay R., Maira M., McNamara K., Perera S.A., Song Y., et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008, 14:1351-1356.
81. Estrela J.M., Ortega A., Obrador E. Glutathione in cancer biology and therapy. Crit Rev Clin Lab Sci 2006, 43:143-181.
82. Evans J.M., Donnelly L.A., Emslie-Smith A.M., Alessi D.R., Morris A.D. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005, 330:1304-1305.
83. Fagotto F., Gumbiner B.M. Cell contact-dependent signaling. Dev Biol 1996, 180:445-454.
84. Fan Y., Dickman K.G., Zong W.X. Akt and c-Myc differentially activate cellular metabolic programs and prime cells to bioenergetic inhibition. J Biol Chem 2010, 285:7324-7333.
85. Fang X., Yu S.X., Lu Y., Bast R.C., Woodgett J.R., Mills G.B. Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Proc Natl Acad Sci USA 2000, 97:11960-11965.
86. Faure Vigny H., Heddi A., Giraud S., Chautard D., Stepien G. Expression of oxidative phosphorylation genes in renal tumors and tumoral cell lines. Mol Carcinog 1996, 16:165-172.
87. Flavin R., Zadra G., Loda M. Metabolic alterations and targeted therapies in prostate cancer. J Pathol 2011, 223:283-294.
88. Fliss M.S., Usadel H., Caballero O.L., Wu L., Buta M.R., Eleff S.M., Jen J., Sidransky D. Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. Science 2000, 287:2017-2019.
89. Friday B.B., Adjei A.A. K-ras as a target for cancer therapy. Biochim Biophys Acta 2005, 1756:127-144.
90. Fujino T., Kondo J., Ishikawa M., Morikawa K., Yamamoto T.T. Acetyl-CoA synthetase 2, a mitochondrial matrix enzyme involved in the oxidation of acetate. J Biol Chem 2001, 276:11420-11426.
91. Gaglio D., Soldati C., Vanoni M., Alberghina L., Chiaradonna F. Glutamine deprivation induces abortive s-phase rescued by deoxyribonucleotides in k-ras transformed fibroblasts. PLoS One 2009, 4:e4715.
92. Gao P., Tchernyshyov I., Chang T.C., Lee Y.S., Kita K., Ochi T., Zeller K.I., De Marzo A.M., Van Eyk J.E., Mendell J.T., et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 2009, 458:762-765.
93. Gasparre G., Porcelli A.M., Bonora E., Pennisi L.F., Toller M., Iommarini L., Ghelli A., Moretti M., Betts C.M., Martinelli G.N., et al. Disruptive mitochondrial DNA mutations in complex I subunits are markers of oncocytic phenotype in thyroid tumors. Proc Natl Acad Sci USA 2007, 104:9001-9006.
94. Gedaly R., Angulo P., Hundley J., Daily M.F., Chen C., Koch A., Evers B.M. PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways. Anticancer Res 2010, 30:4951-4958.
95. Gellerich F.N., Gizatullina Z., Trumbeckaite S., Nguyen H.P., Pallas T., Arandarcikaite O., Vielhaber S., Seppet E., Striggow F. The regulation of OXPHOS by extramitochondrial calcium. Biochim Biophys Acta 2010, 1797:1018-1027.
96. Gerits N., Kostenko S., Shiryaev A., Johannessen M., Moens U. Relations between the mitogen-activated protein kinase and the cAMP-dependent protein kinase pathways: comradeship and hostility. Cell Signal 2008, 20:1592-1607.
97. Gerstle R.J., Aylward S.R., Kromhout-Schiro S., Mukherji S.K. The role of neural networks in improving the accuracy of MR spectroscopy for the diagnosis of head and neck squamous cell carcinoma. AJNR Am J Neuroradiol 2000, 21:1133-1138.
98. Geschwind J.F., Ko Y.H., Torbenson M.S., Magee C., Pedersen P.L. Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP production. Cancer Res 2002, 62:3909-3913.
99. Gottlob K., Majewski N., Kennedy S., Kandel E., Robey R.B., Hay N. Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes Dev 2001, 15:1406-1418.
100. Gough D.J., Corlett A., Schlessinger K., Wegrzyn J., Larner A.C., Levy D.E. Mitochondrial STAT3 supports Ras-dependent oncogenic transformation. Science 2009, 324:1713-1716.
101. Govindarajan B., Sligh J.E., Vincent B.J., Li M., Canter J.A., Nickoloff B.J., Rodenburg R.J., Smeitink J.A., Oberley L., Zhang Y., et al. Overexpression of Akt converts radial growth melanoma to vertical growth melanoma. J Clin Invest 2007, 117:719-729.
102. Grandemange S., Herzig S., Martinou J.C. Mitochondrial dynamics and cancer. Semin Cancer Biol 2009, 19:50-56.
103. Greider B.W., Kallman R.F., Franko A.J. Recruitment of noncycling tumor cells into proliferation by isoproterenol. Cancer Res 1983, 43:1501-1503.
104. Griffin J.L., Sang E., Evens T., Davies K., Clarke K. Metabolic profiles of dystrophin and utrophin expression in mouse models of Duchenne muscular dystrophy. FEBS Lett 2002, 530:109-116.
105. Griffin J.L., Shockcor J.P. Metabolic profiles of cancer cells. Nat Rev Cancer 2004, 4:551-561.
106. Griffiths J.R., McSheehy P.M., Robinson S.P., Troy H., Chung Y.L., Leek R.D., Williams K.J., Stratford I.J., Harris A.L., Stubbs M. Metabolic changes detected by in vivo magnetic resonance studies of HEPA-1 wild-type tumors and tumors deficient in hypoxia-inducible factor-1beta (HIF-1beta): evidence of an anabolic role for the HIF-1 pathway. Cancer Res 2002, 62:688-695.
107. Griffiths J.R., Stubbs M. Opportunities for studying cancer by metabolomics: preliminary observations on tumors deficient in hypoxia-inducible factor 1. Adv Enzyme Regul 2003, 43:67-76.
108. Gupta G.P., Nguyen D.X., Chiang A.C., Bos P.D., Kim J.Y., Nadal C., Gomis R.R., Manova-Todorova K., Massague J. Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature 2007, 446:765-770.
109. Gupta S., Mathur R., Dwarakanath B.S. The glycolytic inhibitor 2-deoxy-d-glucose enhances the efficacy of etoposide in ehrlich ascites tumor-bearing mice. Cancer Biol Ther 2005, 4:87-94.
110. Hagberg G. From magnetic resonance spectroscopy to classification of tumors. A review of pattern recognition methods. NMR Biomed 1998, 11:148-156.
111. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
112. Hanson R.W., Reshef L. Regulation of phosphoenolpyruvate carboxykinase (GTP) gene expression. Annu Rev Biochem 1997, 66:581-611.
113. Hara T., Nakamura K., Matsui M., Yamamoto A., Nakahara Y., Suzuki-Migishima R., Yokoyama M., Mishima K., Saito I., Okano H., et al. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature 2006, 441:885-889.
114. Hartwell L.H., Hopfield J.J., Leibler S., Murray A.W. From molecular to modular cell biology. Nature 1999, 402:C47-C52.
115. Hatzivassiliou G., Zhao F., Bauer D.E., Andreadis C., Shaw A.N., Dhanak D., Hingorani S.R., Tuveson D.A., Thompson C.B. ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell 2005, 8:311-321.
116. He X., Cao X. Identification of alternatively spliced GRIM-19 mRNA in kidney cancer tissues. J Hum Genet 2010, 55:507-511.
117. Heddi A., Faure-Vigny H., Wallace D.C., Stepien G. Coordinate expression of nuclear and mitochondrial genes involved in energy production in carcinoma and oncocytoma. Biochim Biophys Acta 1996, 1316:203-209.
118. Hernlund E., Ihrlund L.S., Khan O., Ates Y.O., Linder S., Panaretakis T., Shoshan M.C. Potentiation of chemotherapeutic drugs by energy metabolism inhibitors 2-deoxyglucose and etomoxir. Int J Cancer 2008, 123:476-483.
119. Hervouet E., Demont J., Pecina P., Vojtiskova A., Houstek J., Simonnet H., Godinot C. A new role for the von Hippel-Lindau tumor suppressor protein: stimulation of mitochondrial oxidative phosphorylation complex biogenesis. Carcinogenesis 2005, 26:531-539.
120. Higuchi M. Regulation of mitochondrial DNA content and cancer. Mitochondrion 2007, 7:53-57.
121. Hiller K., Metallo C.M., Kelleher J.K., Stephanopoulos G. Nontargeted elucidation of metabolic pathways using stable-isotope tracers and mass spectrometry. Anal Chem 2010, 82:6621-6628.
122. Holley R.W., Kiernan J.A. "Contact inhibition" of cell division in 3T3 cells. Proc Natl Acad Sci USA 1968, 60:300-304.
123. Honer M., Ebenhan T., Allegrini P.R., Ametamey S.M., Becquet M., Cannet C., Lane H.A., O'Reilly T.M., Schubiger P.A., Sticker-Jantscheff M., et al. Anti-angiogenic/vascular effects of the mTOR inhibitor everolimus are not detectable by FDG/FLT-PET. Transl Oncol 2010, 3:264-275.
124. Hopper R.K., Carroll S., Aponte A.M., Johnson D.T., French S., Shen R.F., Witzmann F.A., Harris R.A., Balaban R.S. Mitochondrial matrix phosphoproteome: effect of extra mitochondrial calcium. Biochemistry 2006, 45:2524-2536.
125. http://www.advancedcancertherapeutics.com/pipeline.html.
126. http://www.cornerstonepharma.com/clinical-trials.
127. http://www.dynxp.com/index.php/cancer-metabolism/pkm2.
128. http://www.myriadpharma.com/pipeline/mpc-9528.
129. http://www.schebo.com/english/ScheBo_Tumor_M2-PK_EDTA_Plasma_Test_2.php.
130. http://www.tavargenix.com/target.php?site=projects.
131. Hudes G., Carducci M., Tomczak P., Dutcher J., Figlin R., Kapoor A., Staroslawska E., Sosman J., McDermott D., Bodrogi I., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007, 356:2271-2281.
132. Indo H.P., Davidson M., Yen H.C., Suenaga S., Tomita K., Nishii T., Higuchi M., Koga Y., Ozawa T., Majima H.J. Evidence of ROS generation by mitochondria in cells with impaired electron transport chain and mitochondrial DNA damage. Mitochondrion 2007, 7:106-118.
133. Inoki K., Zhu T., Guan K.L. TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003, 115:577-590.
134. Ishikawa K., Takenaga K., Akimoto M., Koshikawa N., Yamaguchi A., Imanishi H., Nakada K., Honma Y., Hayashi J. ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science 2008, 320:661-664.
135. Isidoro A., Martinez M., Fernandez P.L., Ortega A.D., Santamaria G., Chamorro M., Reed J.C., Cuezva J.M. Alteration of the bioenergetic phenotype of mitochondria is a hallmark of breast, gastric, lung and oesophageal cancer. Biochem J 2004, 378:17-20.
136. Ji Z., Flaherty K.T., Tsao H. Molecular therapeutic approaches to melanoma. Mol Aspects Med 2010, 31:194-204.
137. Jones R.G., Plas D.R., Kubek S., Buzzai M., Mu J., Xu Y., Birnbaum M.J., Thompson C.B. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell 2005, 18:283-293.
138. Jordan K.W., Cheng L.L. NMR-based metabolomics approach to target biomarkers for human prostate cancer. Expert Rev Proteomics 2007, 4:389-400.
139. Kaelin W.G., Thompson C.B. Q&A: cancer: clues from cell metabolism. Nature 2010, 465:562-564.
140. Kallinowski F., Vaupel P., Runkel S., Berg G., Fortmeyer H.P., Baessler K.H., Wagner K., Mueller-Klieser W., Walenta S. Glucose uptake, lactate release, ketone body turnover, metabolic micromilieu, and pH distributions in human breast cancer xenografts in nude rats. Cancer Res 1988, 48:7264-7272.
141. Kim H.K., Park W.S., Kang S.H., Warda M., Kim N., Ko J.H., Prince Ael B., Han J. Mitochondrial alterations in human gastric carcinoma cell line. Am J Physiol Cell Physiol 2007, 293:C761-C771.
142. Kim J., Lee J.H., Iyer V.R. Global identification of Myc target genes reveals its direct role in mitochondrial biogenesis and its E-box usage in vivo. PLoS One 2008, 3:e1798.
143. Kim J.W., Tchernyshyov I., Semenza G.L., Dang C.V. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 2006, 3:177-185.
144. Kim L.C., Song L., Haura E.B. Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol 2009, 6:587-595.
145. King M.P., Attardi G. Human cells lacking mtDNA: repopulation with exogenous mitochondria by complementation. Science 1989, 246:500-503.
146. Klionsky D.J. The molecular machinery of autophagy: unanswered questions. J Cell Sci 2005, 118:7-18.
147. Knox W.E., Horowitz M.L., Friedell G.H. The proportionality of glutaminase content to growth rate and morphology of rat neoplasms. Cancer Res 1969, 29:669-680.
148. Komatsu M., Waguri S., Chiba T., Murata S., Iwata J., Tanida I., Ueno T., Koike M., Uchiyama Y., Kominami E., et al. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature 2006, 441:880-884.
149. Komatsu M., Waguri S., Ueno T., Iwata J., Murata S., Tanida I., Ezaki J., Mizushima N., Ohsumi Y., Uchiyama Y., et al. Impairment of starvation-induced and constitutive autophagy in Atg7-deficient mice. J Cell Biol 2005, 169:425-434.
150. Kondoh H., Lleonart M.E., Gil J., Wang J., Degan P., Peters G., Martinez D., Carnero A., Beach D. Glycolytic enzymes can modulate cellular life span. Cancer Res 2005, 65:177-185.
151. Koopman W.J., Verkaart S., Visch H.J., van Emst-de Vries S., Nijtmans L.G., Smeitink J.A., Willems P.H. Human NADH:ubiquinone oxidoreductase deficiency: radical changes in mitochondrial morphology?. Am J Physiol Cell Physiol 2007, 293:C22-C29.
152. Kridel S.J., Axelrod F., Rozenkrantz N., Smith J.W. Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res 2004, 64:2070-2075.
153. Krieg R.C., Knuechel R., Schiffmann E., Liotta L.A., Petricoin E.F., Herrmann P.C. Mitochondrial proteome: cancer-altered metabolism associated with cytochrome c oxidase subunit level variation. Proteomics 2004, 4:2789-2795.
154. Kroemer G., Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 2008, 13:472-482.
155. Kuhajda F.P. Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition 2000, 16:202-208.
156. Kuhajda F.P., Pizer E.S., Li J.N., Mani N.S., Frehywot G.L., Townsend C.A. Synthesis and antitumor activity of an inhibitor of fatty acid synthase. Proc Natl Acad Sci USA 2000, 97:3450-3454.
157. Kuhn K.S., Schuhmann K., Stehle P., Darmaun D., Furst P. Determination of glutamine in muscle protein facilitates accurate assessment of proteolysis and de novo synthesis-derived endogenous glutamine production. Am J Clin Nutr 1999, 70:484-489.
158. Kuma A., Hatano M., Matsui M., Yamamoto A., Nakaya H., Yoshimori T., Ohsumi Y., Tokuhisa T., Mizushima N. The role of autophagy during the early neonatal starvation period. Nature 2004, 432:1032-1036.
159. Kumar R., Halanaik D., Malhotra A. Clinical applications of positron emission tomography-computed tomography in oncology. Indian J Cancer 2010, 47:100-119.
160. Kuppers M., Ittrich C., Faust D., Dietrich C. The transcriptional programme of contact-inhibition. J Cell Biochem 2010, 110:1234-1243.
161. LaCasse E.C., Mahoney D.J., Cheung H.H., Plenchette S., Baird S., Korneluk R.G. IAP-targeted therapies for cancer. Oncogene 2008, 27:6252-6275.
162. Laviano A., Cascino A., Muscaritoli M., Fanfarillo F., Rossi Fanelli F. Tumor-induced changes in host metabolism: a possible role for free tryptophan as a marker of neoplastic disease. Adv Exp Med Biol 2003, 527:363-366.
163. Leavens W.J., Lane S.J., Carr R.M., Lockie A.M., Waterhouse I. Derivatization for liquid chromatography/electrospray mass spectrometry: synthesis of tris(trimethoxyphenyl)phosphonium compounds and their derivatives of amine and carboxylic acids. Rapid Commun Mass Spectrom 2002, 16:433-441.
164. Lee C., Safdie F.M., Raffaghello L., Wei M., Madia F., Parrella E., Hwang D., Cohen P., Bianchi G., Longo V.D. Reduced levels of IGF-I mediate differential protection of normal and cancer cells in response to fasting and improve chemotherapeutic index. Cancer Res 2010, 70:1564-1572.
165. Lee H.C., Wei Y.H. Mitochondrial DNA instability and metabolic shift in human cancers. Int J Mol Sci 2009, 10:674-701.
166. Lemons J.M., Feng X.J., Bennett B.D., Legesse-Miller A., Johnson E.L., Raitman I., Pollina E.A., Rabitz H.A., Rabinowitz J.D., Coller H.A. Quiescent fibroblasts exhibit high metabolic activity. PLoS Biol 2010, 8:e1000514.
167. Levine A.J., Puzio-Kuter A.M. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 2010, 330:1340-1344.
168. Li F., Wang Y., Zeller K.I., Potter J.J., Wonsey D.R., O'Donnell K.A., Kim J.W., Yustein J.T., Lee L.A., Dang C.V. Myc stimulates nuclearly encoded mitochondrial genes and mitochondrial biogenesis. Mol Cell Biol 2005, 25:6225-6234.
169. Lin Y., Fukuchi J., Hiipakka R.A., Kokontis J.M., Xiang J. Up-regulation of Bcl-2 is required for the progression of prostate cancer cells from an androgen-dependent to an androgen-independent growth stage. Cell Res 2007, 17:531-536.
170. Lin Y.Y., Lu J.Y., Zhang J., Walter W., Dang W., Wan J., Tao S.C., Qian J., Zhao Y., Boeke J.D., et al. Protein acetylation microarray reveals that NuA4 controls key metabolic target regulating gluconeogenesis. Cell 2009, 136:1073-1084.
171. Linder-Horowitz M., Knox W.E., Morris H.P. Glutaminase activities and growth rates of rat hepatomas. Cancer Res 1969, 29:1195-1199.
172. Lindon J.C., Holmes E., Nicholson J.K. So what's the deal with metabonomics?. Anal Chem 2003, 75:384A-391A.
173. Lindon J.C., Nicholson J.K., Holmes E., Antti H., Bollard M.E., Keun H., Beckonert O., Ebbels T.M., Reily M.D., Robertson D., et al. Contemporary issues in toxicology the role of metabonomics in toxicology and its evaluation by the COMET project. Toxicol Appl Pharmacol 2003, 187:137-146.
174. Linehan W.M., Srinivasan R., Schmidt L.S. The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol 2010, 7:277-285.
175. Liu Y. Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer. Prostate Cancer Prostatic Dis 2006, 9:230-234.
176. Lobo C., Ruiz-Bellido M.A., Aledo J.C., Marquez J., Nunez De Castro I., Alonso F.J. Inhibition of glutaminase expression by antisense mRNA decreases growth and tumourigenicity of tumour cells. Biochem J 2000, 348(Pt 2):257-261.
177. Lopez-Rios F., Sanchez-Arago M., Garcia-Garcia E., Ortega A.D., Berrendero J.R., Pozo-Rodriguez F., Lopez-Encuentra A., Ballestin C., Cuezva J.M. Loss of the mitochondrial bioenergetic capacity underlies the glucose avidity of carcinomas. Cancer Res 2007, 67:9013-9017.
178. Lu J., Sharma L.K., Bai Y. Implications of mitochondrial DNA mutations and mitochondrial dysfunction in tumorigenesis. Cell Res 2009, 19:802-815.
179. Lum J.J., Bauer D.E., Kong M., Harris M.H., Li C., Lindsten T., Thompson C.B. Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell 2005, 120:237-248.
180. Luo Z., Zang M., Guo W. AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. Future Oncol 2010, 6:457-470.
181. Malumbres M., Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 2001, 1:222-231.
182. Mamelak A.J., Kowalski J., Murphy K., Yadava N., Zahurak M., Kouba D.J., Howell B.G., Tzu J., Cummins D.L., Liegeois N.J., et al. Downregulation of NDUFA1 and other oxidative phosphorylation-related genes is a consistent feature of basal cell carcinoma. Exp Dermatol 2005, 14:336-348.
183. Marnett L.J. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res 1992, 52:5575-5589.
184. Maschek G., Savaraj N., Priebe W., Braunschweiger P., Hamilton K., Tidmarsh G.F., De Young L.R., Lampidis T.J. 2-deoxy-d-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res 2004, 64:31-34.
185. Mashima T., Seimiya H., Tsuruo T. De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy. Br J Cancer 2009, 100:1369-1372.
186. Mathupala S.P., Heese C., Pedersen P.L. Glucose catabolism in cancer cells. The type II hexokinase promoter contains functionally active response elements for the tumor suppressor p53. J Biol Chem 1997, 272:22776-22780.
187. Matoba S., Kang J.G., Patino W.D., Wragg A., Boehm M., Gavrilova O., Hurley P.J., Bunz F., Hwang P.M. p53 regulates mitochondrial respiration. Science 2006, 312:1650-1653.
188. Medes G., Thomas A., Weinhouse S. Metabolism of neoplastic tissue. IV. A study of lipid synthesis in neoplastic tissue slices in vitro. Cancer Res 1953, 13:27-29.
189. Medina M.A., Sanchez-Jimenez F., Marquez J., Rodriguez Quesada A., Nunez de Castro I. Relevance of glutamine metabolism to tumor cell growth. Mol Cell Biochem 1992, 113:1-15.
190. Mellanen P., Minn H., Grenman R., Harkonen P. Expression of glucose transporters in head-and-neck tumors. Int J Cancer 1994, 56:622-629.
191. Menendez J.A., Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 2007, 7:763-777.
192. Menendez J.A., Vellon L., Colomer R., Lupu R. Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity. Int J Cancer 2005, 115:19-35.
193. Metallo C.M., Walther J.L., Stephanopoulos G. Evaluation of 13C isotopic tracers for metabolic flux analysis in mammalian cells. J Biotechnol 2009, 144:167-174.
194. Michelakis E.D., Sutendra G., Dromparis P., Webster L., Haromy A., Niven E., Maguire C., Gammer T.L., Mackey J.R., Fulton D., et al. Metabolic modulation of glioblastoma with dichloroacetate. Sci Transl Med 2010, 2:31-34.
195. Miller A.L. Therapeutic considerations of l-glutamine: a review of the literature. Altern Med Rev 1999, 4:239-248.
196. Mills G.B., Moolenaar W.H. The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 2003, 3:582-591.
197. Mochizuki T., Tsukamoto E., Kuge Y., Kanegae K., Zhao S., Hikosaka K., Hosokawa M., Kohanawa M., Tamaki N. FDG uptake and glucose transporter subtype expressions in experimental tumor and inflammation models. J Nucl Med 2001, 42:1551-1555.
198. Modica-Napolitano J.S., Singh K.K. Mitochondrial dysfunction in cancer. Mitochondrion 2004, 4:755-762.
199. Moiseeva O., Bourdeau V., Roux A., Deschenes-Simard X., Ferbeyre G. Mitochondrial dysfunction contributes to oncogene-induced senescence. Mol Cell Biol 2009, 29:4495-4507.
200. Moreadith R.W., Lehninger A.L. The pathways of glutamate and glutamine oxidation by tumor cell mitochondria. Role of mitochondrial NAD(P)+-dependent malic enzyme. J Biol Chem 1984, 259:6215-6221.
201. Motzer R.J., Escudier B., Oudard S., Hutson T.E., Porta C., Bracarda S., Grunwald V., Thompson J.A., Figlin R.A., Hollaender N., et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008, 372:449-456.
202. Motzer R.J., Hudes G.R., Curti B.D., McDermott D.F., Escudier B.J., Negrier S., Duclos B., Moore L., O'Toole T., Boni J.P., et al. Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma. J Clin Oncol 2007, 25:3958-3964.
203. Nadolski M.J., Linder M.E. Protein lipidation. FEBS J 2007, 274:5202-5210.
204. Nagase Y., Takata K., Moriyama N., Aso Y., Murakami T., Hirano H. Immunohistochemical localization of glucose transporters in human renal cell carcinoma. J Urol 1995, 153:798-801.
205. Negrini S., Gorgoulis V.G., Halazonetis T.D. Genomic instability-an evolving hallmark of cancer. Nat Rev Mol Cell Biol 2010, 11:220-228.
206. Newsholme P., Lima M.M., Procopio J., Pithon-Curi T.C., Doi S.Q., Bazotte R.B., Curi R. Glutamine and glutamate as vital metabolites. Revista brasileira de pesquisas medicas e biologicas/Sociedade Brasileira de Biofisica 2003, 36:153-163. Brazilian Journal of Medical and Biological Research, et al.
207. Newsholme P., Procopio J., Lima M.M., Pithon-Curi T.C., Curi R. Glutamine and glutamate-their central role in cell metabolism and function. Cell Biochem Funct 2003, 21:1-9.
208. Nicholson J.K., Connelly J., Lindon J.C., Holmes E. Metabonomics: a platform for studying drug toxicity and gene function. Nat Rev Drug Discov 2002, 1:153-161.
209. Nilsson R., Schultz I.J., Pierce E.L., Soltis K.A., Naranuntarat A., Ward D.M., Baughman J.M., Paradkar P.N., Kingsley P.D., Culotta V.C., et al. Discovery of genes essential for heme biosynthesis through large-scale gene expression analysis. Cell Metab 2009, 10:119-130.
210. Nomura D.K., Long J.Z., Niessen S., Hoover H.S., Ng S.W., Cravatt B.F. Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell 2010, 140:49-61.
211. O'Day S., Gonzalez R., Lawson D., Weber R., Hutchins L., Anderson C., Haddad J., Kong S., Williams A., Jacobson E. Phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma. J Clin Oncol 2009, 27:5452-5458.
212. Ohta S. Contribution of somatic mutations in the mitochondrial genome to the development of cancer and tolerance against anticancer drugs. Oncogene 2006, 25:4768-4776.
213. Oldiges M., Lutz S., Pflug S., Schroer K., Stein N., Wiendahl C. Metabolomics: current state and evolving methodologies and tools. Appl Microbiol Biotechnol 2007, 76:495-511.
214. Papa S., De Rasmo D., Scacco S., Signorile A., Technikova-Dobrova Z., Palmisano G., Sardanelli A.M., Papa F., Panelli D., Scaringi R., et al. Mammalian complex I: a regulable and vulnerable pacemaker in mitochondrial respiratory function. Biochim Biophys Acta 2008, 1777:719-728.
215. Papandreou I., Cairns R.A., Fontana L., Lim A.L., Denko N.C. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab 2006, 3:187-197.
216. Park J.W., Kim J.H., Kim S.K., Kang K.W., Park K.W., Choi J.I., Lee W.J., Kim C.M., Nam B.H. A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma. J Nucl Med 2008, 49:1912-1921.
217. Parsons S.J., Parsons J.T. Src family kinases, key regulators of signal transduction. Oncogene 2004, 23:7906-7909.
218. Pelicano H., Martin D.S., Xu R.H., Huang P. Glycolysis inhibition for anticancer treatment. Oncogene 2006, 25:4633-4646.
219. Penta J.S., Johnson F.M., Wachsman J.T., Copeland W.C. Mitochondrial DNA in human malignancy. Mutat Res 2001, 488:119-133.
220. Perumal V., Solomon P.F., Jayanth V.R. Modification of 2-deoxy-d-glucose on radiation- and chemotherapeutic drug-induced chromosomal aberrations. J Cancer Res Ther 2009, 5(Suppl 1):S48-S52.
221. Petros J.A., Baumann A.K., Ruiz-Pesini E., Amin M.B., Sun C.Q., Hall J., Lim S., Issa M.M., Flanders W.D., Hosseini S.H., et al. mtDNA mutations increase tumorigenicity in prostate cancer. Proc Natl Acad Sci USA 2005, 102:719-724.
222. Pfeuffer J., Tkac I., Provencher S.W., Gruetter R. Toward an in vivo neurochemical profile: quantification of 18 metabolites in short-echo-time (1)H NMR spectra of the rat brain. J Magn Reson 1999, 141:104-120.
223. Pillay V., Allaf L., Wilding A.L., Donoghue J.F., Court N.W., Greenall S.A., Scott A.M., Johns T.G. The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases. Neoplasia 2009, 11:448-458. 442 p following 458.
224. Pizer E.S., Thupari J., Han W.F., Pinn M.L., Chrest F.J., Frehywot G.L., Townsend C.A., Kuhajda F.P. Malonyl-coenzyme-A is a potential mediator of cytotoxicity induced by fatty-acid synthase inhibition in human breast cancer cells and xenografts. Cancer Res 2000, 60:213-218.
225. Porstmann T., Griffiths B., Chung Y.L., Delpuech O., Griffiths J.R., Downward J., Schulze A. PKB/Akt induces transcription of enzymes involved in cholesterol and fatty acid biosynthesis via activation of SREBP. Oncogene 2005, 24:6465-6481.
226. Porstmann T., Santos C.R., Lewis C., Griffiths B., Schulze A. A new player in the orchestra of cell growth: SREBP activity is regulated by mTORC1 and contributes to the regulation of cell and organ size. Biochem Soc Trans 2009, 37:278-283.
227. Puig T., Relat J., Marrero P.F., Haro D., Brunet J., Colomer R. Green tea catechin inhibits fatty acid synthase without stimulating carnitine palmitoyltransferase-1 or inducing weight loss in experimental animals. Anticancer Res 2008, 28:3671-3676.
228. Puig T., Turrado C., Benhamu B., Aguilar H., Relat J., Ortega-Gutierrez S., Casals G., Marrero P.F., Urruticoechea A., Haro D., et al. Novel inhibitors of fatty acid synthase with anticancer activity. Clin Cancer Res 2009, 15:7608-7615.
229. Qu Y., Wang J., Sim M.S., Liu B., Giuliano A., Barsoum J., Cui X. Elesclomol, counteracted by Akt survival signaling, enhances the apoptotic effect of chemotherapy drugs in breast cancer cells. Breast Cancer Res Treat 2010, 121:311-321.
230. Rajendran J.G., Mankoff D.A., O'Sullivan F., Peterson L.M., Schwartz D.L., Conrad E.U., Spence A.M., Muzi M., Farwell D.G., Krohn K.A. Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res 2004, 10:2245-2252.
231. Ramanathan A., Wang C., Schreiber S.L. Perturbational profiling of a cell-line model of tumorigenesis by using metabolic measurements. Proc Natl Acad Sci USA 2005, 102:5992-5997.
232. Rathmell J.C., Fox C.J., Plas D.R., Hammerman P.S., Cinalli R.M., Thompson C.B. Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival. Mol Cell Biol 2003, 23:7315-7328.
233. Reitzer L.J., Wice B.M., Kennell D. Evidence that glutamine, not sugar, is the major energy source for cultured HeLa cells. J Biol Chem 1979, 254:2669-2676.
234. Ren J., Xiao Y.J., Singh L.S., Zhao X., Zhao Z., Feng L., Rose T.M., Prestwich G.D., Xu Y. Lysophosphatidic acid is constitutively produced by human peritoneal mesothelial cells and enhances adhesion, migration, and invasion of ovarian cancer cells. Cancer Res 2006, 66:3006-3014.
235. Richter C., Park J.W., Ames B.N. Normal oxidative damage to mitochondrial and nuclear DNA is extensive. Proc Natl Acad Sci USA 1988, 85:6465-6467.
236. Rocha C.M., Barros A.S., Gil A.M., Goodfellow B.J., Humpfer E., Spraul M., Carreira I.M., Melo J.B., Bernardo J., Gomes A., et al. Metabolic profiling of human lung cancer tissue by 1H high resolution magic angle spinning (HRMAS) NMR spectroscopy. J Proteome Res 2010, 9:319-332.
237. Roessner U., Wagner C., Kopka J., Trethewey R.N., Willmitzer L. Technical advance: simultaneous analysis of metabolites in potato tuber by gas chromatography-mass spectrometry. Plant J 2000, 23:131-142.
238. Samudio I., Harmancey R., Fiegl M., Kantarjian H., Konopleva M., Korchin B., Kaluarachchi K., Bornmann W., Duvvuri S., Taegtmeyer H., et al. Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J Clin Invest 2010, 120:142-156.
239. Sauer L.A., Stayman J.W., Dauchy R.T. Amino acid, glucose, and lactic acid utilization in vivo by rat tumors. Cancer Res 1982, 42:4090-4097.
240. Sauvanet C., Duvezin-Caubet S., di Rago J.P., Rojo M. Energetic requirements and bioenergetic modulation of mitochondrial morphology and dynamics. Semin Cell Dev Biol 2010, 21:558-565.
241. Schoder H., Larson S.M. Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med 2004, 34:274-292.
242. Schulz T.J., Thierbach R., Voigt A., Drewes G., Mietzner B., Steinberg P., Pfeiffer A.F., Ristow M. Induction of oxidative metabolism by mitochondrial frataxin inhibits cancer growth: Otto Warburg revisited. J Biol Chem 2006, 281:977-981.
243. Schulze F., Vollert J., Maas R., Muller R., Schwedhelm E., Muller C., Boger R.H., Mockel M. Asymmetric dimethylarginine predicts outcome and time of stay in hospital in patients attending an internal medicine emergency room. Clin Chim Acta 2009, 401:20-24.
244. Schwartzenberg-Bar-Yoseph F., Armoni M., Karnieli E. The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression. Cancer Res 2004, 64:2627-2633.
245. Seltzer M.J., Bennett B.D., Joshi A.D., Gao P., Thomas A.G., Ferraris D.V., Tsukamoto T., Rojas C.J., Slusher B.S., Rabinowitz J.D., et al. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res 2010, 70:8981-8987.
246. Semenza G.L. HIF-1 mediates the Warburg effect in clear cell renal carcinoma. J Bioenerg Biomembr 2007, 39:231-234.
247. Shankar L.K., Hoffman J.M., Bacharach S., Graham M.M., Karp J., Lammertsma A.A., Larson S., Mankoff D.A., Siegel B.A., Van den Abbeele A., et al. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med 2006, 47:1059-1066.
248. Sharp M.G., Adams S.M., Walker R.A., Brammar W.J., Varley J.M. Differential expression of the mitochondrial gene cytochrome oxidase II in benign and malignant breast tissue. J Pathol 1992, 168:163-168.
249. Shaw R.J., Bardeesy N., Manning B.D., Lopez L., Kosmatka M., DePinho R.A., Cantley L.C. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 2004, 6:91-99.
250. Shen L., Fang H., Chen T., He J., Zhang M., Wei X., Xin Y., Jiang Y., Ding Z., Ji J., et al. Evaluating mitochondrial DNA in cancer occurrence and development. Ann N Y Acad Sci 2010, 1201:26-33.
251. Shidara Y., Yamagata K., Kanamori T., Nakano K., Kwong J.Q., Manfredi G., Oda H., Ohta S. Positive contribution of pathogenic mutations in the mitochondrial genome to the promotion of cancer by prevention from apoptosis. Cancer Res 2005, 65:1655-1663.
252. Shimizu T., Okamoto I., Tamura K., Satoh T., Miyazaki M., Akashi Y., Ozaki T., Fukuoka M., Nakagawa K. Phase I clinical and pharmacokinetic study of the glucose-conjugated cytotoxic agent D: -19575 (glufosfamide) in patients with solid tumors. Cancer Chemother Pharmacol 2009, 65:243-250.
253. Simons A.L., Mattson D.M., Dornfeld K., Spitz D.R. Glucose deprivation-induced metabolic oxidative stress and cancer therapy. J Cancer Res Ther 2009, 5(Suppl 1):S2-S6.
254. Smith T.A., Sharma R.I., Thompson A.M., Paulin F.E. Tumor 18F-FDG incorporation is enhanced by attenuation of P53 function in breast cancer cells in vitro. J Nucl Med 2006, 47:1525-1530.
255. Spitz D.R., Sim J.E., Ridnour L.A., Galoforo S.S., Lee Y.J. Glucose deprivation-induced oxidative stress in human tumor cells. A fundamental defect in metabolism?. Ann N Y Acad Sci 2000, 899:349-362.
256. Srivastava S., Barrett J.N., Moraes C.T. PGC-1alpha/beta upregulation is associated with improved oxidative phosphorylation in cells harboring nonsense mtDNA mutations. Hum Mol Genet 2007, 16:993-1005.
257. Stass S.A., Mixson J. Oncogenes and tumor suppressor genes: therapeutic implications. Clin Cancer Res 1997, 3:2687-2695.
258. Stein M., Lin H., Jeyamohan C., Dvorzhinski D., Gounder M., Bray K., Eddy S., Goodin S., White E., Dipaola R.S. Targeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignancies. Prostate 2010, 70:1388-1394.
259. Sunaga N., Oriuchi N., Kaira K., Yanagitani N., Tomizawa Y., Hisada T., Ishizuka T., Endo K., Mori M. Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer. Lung Cancer 2008, 59:203-210.
260. Suzuki S., Tanaka T., Poyurovsky M.V., Nagano H., Mayama T., Ohkubo S., Lokshin M., Hosokawa H., Nakayama T., Suzuki Y., et al. Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species. Proc Natl Acad Sci USA 2010, 107:7461-7466.
261. Szuba A., Chachaj A., Wrobel T., Dzietczenia J., Mazur G., Antonowicz-Juchniewicz J., Kuliczkowski K., Andrzejak R. Asymmetric dimethylarginine in hematological malignancies: a preliminary study. Leuk Lymphoma 2008, 49:2316-2320.
262. Taguchi N., Ishihara N., Jofuku A., Oka T., Mihara K. Mitotic phosphorylation of dynamin-related GTPase Drp1 participates in mitochondrial fission. J Biol Chem 2007, 282:11521-11529.
263. Takahashi E., Sato M. Imaging of oxygen gradients in monolayer cultured cells using green fluorescent protein. Am J Physiol Cell Physiol 2010, 299:C1318-C1323.
264. Tamura Y., Simizu S., Osada H. The phosphorylation status and anti-apoptotic activity of Bcl-2 are regulated by ERK and protein phosphatase 2A on the mitochondria. FEBS Lett 2004, 569:249-255.
265. Tang Y.J., Martin H.G., Myers S., Rodriguez S., Baidoo E.E., Keasling J.D. Advances in analysis of microbial metabolic fluxes via (13)C isotopic labeling. Mass Spectrom Rev 2009, 28:362-375.
266. Terrano D.T., Upreti M., Chambers T.C. Cyclin-dependent kinase 1-mediated Bcl-xL/Bcl-2 phosphorylation acts as a functional link coupling mitotic arrest and apoptosis. Mol Cell Biol 2010, 30:640-656.
267. Thomson M. Evidence of undiscovered cell regulatory mechanisms: phosphoproteins and protein kinases in mitochondria. Cell Mol Life Sci 2002, 59:213-219.
268. Thornburg J.M., Nelson K.K., Clem B.F., Lane A.N., Arumugam S., Simmons A., Eaton J.W., Telang S., Chesney J. Targeting aspartate aminotransferase in breast cancer. Breast Cancer Res 2008, 10:R84.
269. Tibaldi E., Brunati A.M., Massimino M.L., Stringaro A., Colone M., Agostinelli E., Arancia G., Toninello A. Src-Tyrosine kinases are major agents in mitochondrial tyrosine phosphorylation. J Cell Biochem 2008, 104:840-849.
270. Twig G., Elorza A., Molina A.J., Mohamed H., Wikstrom J.D., Walzer G., Stiles L., Haigh S.E., Katz S., Las G., et al. Fission and selective fusion govern mitochondrial segregation and elimination by autophagy. EMBO J 2008, 27:433-446.
271. Vander Heiden M.G., Cantley L.C., Thompson C.B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324:1029-1033.
272. Vander Heiden M.G., Locasale J.W., Swanson K.D., Sharfi H., Heffron G.J., Amador-Noguez D., Christofk H.R., Wagner G., Rabinowitz J.D., Asara J.M., et al. Evidence for an alternative glycolytic pathway in rapidly proliferating cells. Science 2010, 329:1492-1499.
273. Vander Heiden M.G., Plas D.R., Rathmell J.C., Fox C.J., Harris M.H., Thompson C.B. Growth factors can influence cell growth and survival through effects on glucose metabolism. Mol Cell Biol 2001, 21:5899-5912.
274. Vaupel P., Kallinowski F., Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 1989, 49:6449-6465.
275. Vaupel P., Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 2007, 26:225-239.
276. Vinci E., Rampello E., Zanoli L., Oreste G., Pistone G., Malaguarnera M. Serum carnitine levels in patients with tumoral cachexia. Eur J Intern Med 2005, 16:419-423.
277. Wang J.B., Erickson J.W., Fuji R., Ramachandran S., Gao P., Dinavahi R., Wilson K.F., Ambrosio A.L., Dias S.M., Dang C.V., et al. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell 2010, 18:207-219.
278. Wang J.H., Byun J., Pennathur S. Analytical approaches to metabolomics and applications to systems biology. Semin Nephrol 2010, 30:500-511.
279. Wang M.Y., Chen P.S., Prakash E., Hsu H.C., Huang H.Y., Lin M.T., Chang K.J., Kuo M.L. Connective tissue growth factor confers drug resistance in breast cancer through concomitant up-regulation of Bcl-xL and cIAP1. Cancer Res 2009, 69:3482-3491.
280. Wangpaichitr M., Savaraj N., Maher J., Kurtoglu M., Lampidis T.J. Intrinsically lower AKT, mammalian target of rapamycin, and hypoxia-inducible factor activity correlates with increased sensitivity to 2-deoxy-d-glucose under hypoxia in lung cancer cell lines. Mol Cancer Ther 2008, 7:1506-1513.
281. Warburg O. On the origin of cancer cells. Science 1956, 123:309-314.
282. Wellen K.E., Hatzivassiliou G., Sachdeva U.M., Bui T.V., Cross J.R., Thompson C.B. ATP-citrate lyase links cellular metabolism to histone acetylation. Science 2009, 324:1076-1080.
283. Wenger J.B., Chun S.Y., Dang D.T., Luesch H., Dang L.H. Combination therapy targeting cancer metabolism. Med Hypotheses 2010, 76:169-172.
284. Westermann B. Mitochondrial fusion and fission in cell life and death. Nat Rev Mol Cell Biol 2010, 11:872-884.
285. Wise D.R., Thompson C.B. Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci 2010, 35:427-433.
286. Wolpin B.M., Hezel A.F., Abrams T., Blaszkowsky L.S., Meyerhardt J.A., Chan J.A., Enzinger P.C., Allen B., Clark J.W., Ryan D.P., et al. Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol 2009, 27:193-198.
287. Wu L., Zhou L., Liu D.Q., Vogt F.G., Kord A.S. LC-MS/MS and density functional theory study of copper(II) and nickel(II) chelating complexes of elesclomol (a novel anticancer agent). J Pharm Biomed Anal 2011, 54:331-336.
288. Xue L., Gollapalli D.R., Maiti P., Jahng W.J., Rando R.R. A palmitoylation switch mechanism in the regulation of the visual cycle. Cell 2004, 117:761-771.
289. Yamamoto A., Horai S., Yuasa Y. Increased level of mitochondrial gene expression in polyps of familial polyposis coli patients. Biochem Biophys Res Commun 1989, 159:1100-1106.
290. Yamamoto T., Seino Y., Fukumoto H., Koh G., Yano H., Inagaki N., Yamada Y., Inoue K., Manabe T., Imura H. Over-expression of facilitative glucose transporter genes in human cancer. Biochem Biophys Res Commun 1990, 170:223-230.
291. Yang C., Richardson A.D., Osterman A., Smith J.W. Profiling of central metabolism in human cancer cells by two-dimensional NMR. Metabolomics 2008, 4:13-29.
292. Yang D., Wang M.T., Tang Y., Chen Y., Jiang H., Jones T.T., Rao K., Brewer G.J., Singh K.K., Nie D. Impairment of mitochondrial respiration in mouse fibroblasts by oncogenic H-RAS(Q61L). Cancer Biol Ther 2010, 9:122-133.
293. Yoshii Y., Waki A., Furukawa T., Kiyono Y., Mori T., Yoshii H., Kudo T., Okazawa H., Welch M.J., Fujibayashi Y. Tumor uptake of radiolabeled acetate reflects the expression of cytosolic acetyl-CoA synthetase: implications for the mechanism of acetate PET. Nucl Med Biol 2009, 36:771-777.
294. Younes M., Lechago L.V., Somoano J.R., Mosharaf M., Lechago J. Immunohistochemical detection of Glut3 in human tumors and normal tissues. Anticancer Res 1997, 17:2747-2750.
295. Young V.R., Ajami A.M. Glutamine: the emperor or his clothes?. J Nutr 2001, 131:2449S-2459S. discussion 2486S-2447S.
296. Yu C., Minemoto Y., Zhang J., Liu J., Tang F., Bui T.N., Xiang J., Lin A. JNK suppresses apoptosis via phosphorylation of the proapoptotic Bcl-2 family protein BAD. Mol Cell 2004, 13:329-340.
297. Yu K., Shi C., Toral-Barza L., Lucas J., Shor B., Kim J.E., Zhang W.G., Mahoney R., Gaydos C., Tardio L., et al. Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2. Cancer Res 2010, 70:621-631.
298. Yuan T.L., Cantley L.C. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008, 27:5497-5510.
299. Yun J., Rago C., Cheong I., Pagliarini R., Angenendt P., Rajagopalan H., Schmidt K., Willson J.K., Markowitz S., Zhou S., et al. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science 2009, 325:1555-1559.
300. Zhou G., Myers R., Li Y., Chen Y., Shen X., Fenyk-Melody J., Wu M., Ventre J., Doebber T., Fujii N., et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001, 108:1167-1174.
301. Zhou W., Han W.F., Landree L.E., Thupari J.N., Pinn M.L., Bililign T., Kim E.K., Vadlamudi A., Medghalchi S.M., El Meskini R., et al. Fatty acid synthase inhibition activates AMP-activated protein kinase in SKOV3 human ovarian cancer cells. Cancer Res 2007, 67:2964-2971.
302. Zhuang Y., Miskimins W.K. Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1. J Mol Signal 2008, 3:18.
303. Zimmermann F.A., Mayr J.A., Neureiter D., Feichtinger R., Alinger B., Jones N.D., Eder W., Sperl W., Kofler B. Lack of complex I is associated with oncocytic thyroid tumours. Br J Cancer 2009, 100:1434-1437.
304. Zong W.X., Ditsworth D., Bauer D.E., Wang Z.Q., Thompson C.B. Alkylating DNA damage stimulates a regulated form of necrotic cell death. Genes Dev 2004, 18:1272-1282.
305. Zong W.X., Thompson C.B. Necrotic death as a cell fate. Genes Dev 2006, 20:1-15.
306. Zunder E.R., Knight Z.A., Houseman B.T., Apsel B., Shokat K.M. Discovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110 alpha. Cancer Cell 2008, 14:180-192.